Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Journey Medical Corporation is a commercial-stage dermatology company marketing a portfolio of branded and generic prescription dermatological products in the U.S. market. The company operates through promotional partnerships and direct sales, focusing on treatments for acne, rosacea, and other skin conditions. Recent financials show significant revenue contraction (-29% YoY) and negative cash flow, indicating operational challenges in a competitive specialty pharma landscape.
Journey generates revenue by marketing and distributing dermatology products through a specialized sales force targeting dermatologists and primary care physicians. The company acquires or licenses products with established safety profiles, then leverages promotional capabilities to drive prescription volume. Gross margins of 63% reflect typical specialty pharma economics, but the company operates at negative EBITDA due to high SG&A costs (sales force, marketing) relative to current revenue base. Pricing power is limited by generic competition and pharmacy benefit manager formulary positioning.
Prescription volume trends for key branded products, particularly any new product launches or label expansions
Formulary wins or losses with major pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) affecting reimbursement access
Sales force productivity metrics and physician call activity in target dermatology practices
Generic competition introductions for branded products or pricing pressure in generic portfolio
Partnership announcements for new product acquisitions or co-promotion agreements
Pharmacy benefit manager consolidation and increasing formulary restrictions reducing reimbursement access for branded dermatology products
Generic drug price erosion driven by FDA approval acceleration and increased competition in dermatology segment
Shift toward biosimilars and novel mechanisms in dermatology (biologics for psoriasis, atopic dermatitis) potentially obsoleting traditional small-molecule treatments
Competition from larger dermatology-focused companies (Bausch Health, Sun Pharma, Valeant legacy assets) with greater scale and formulary leverage
Direct-to-consumer telemedicine dermatology platforms (Hims & Hers, Curology) disrupting traditional physician-driven prescription model for acne and anti-aging treatments
Negative operating cash flow of $3.5M (annualized) and cash burn requiring external financing within 12-18 months at current trajectory
Debt/equity ratio of 0.98 limits additional borrowing capacity; equity raises would be dilutive at current valuation
Revenue decline of 29% YoY suggests potential going-concern issues if trend continues without operational restructuring
low - Prescription dermatology products are generally non-discretionary medical treatments with stable demand across economic cycles. However, elective cosmetic dermatology procedures that drive office visits may see modest cyclical variation. Insurance coverage insulates most demand from consumer spending fluctuations, though high-deductible health plans may create some price sensitivity for branded products.
Rising interest rates create moderate pressure through two channels: (1) higher cost of capital for a cash-burning business with debt/equity of 0.98, potentially requiring dilutive equity raises if credit markets tighten, and (2) valuation multiple compression as investors demand higher returns from unprofitable growth companies. The company's negative free cash flow makes it vulnerable to financing conditions.
Moderate exposure. The company's ability to fund operations depends on access to credit markets or equity capital given negative operating cash flow. Tightening credit conditions or widening high-yield spreads would increase financing costs and potentially limit strategic flexibility for product acquisitions. Current ratio of 1.42 provides modest liquidity cushion.
momentum - The 58% one-year return despite deteriorating fundamentals suggests speculative trading interest, likely driven by technical factors or turnaround speculation rather than fundamental value. The combination of negative margins, declining revenue, and micro-cap status attracts high-risk tolerance investors seeking asymmetric upside from potential restructuring, product pipeline developments, or acquisition speculation. Not suitable for value or income investors given negative earnings and no dividend.
high - Micro-cap healthcare stock with $200M market cap, negative cash flow, and binary outcomes around product performance creates elevated volatility. Limited analyst coverage and low trading liquidity amplify price swings on company-specific news. Estimated beta likely exceeds 1.5 relative to healthcare sector.
